Initiatives mondiales

Auteur: Charles H. Hoke, Vivien D. Tsu, Julie A. Jacobson, Theodore F. Tsai, Marc Fischer, Tom Solomon, Susan L. Hills, Anthony A. Marfin, Grant L. Campbell, Joachim M. Hombach, Amy S. Ginsburg

Policy paper: At the midpoint of the Decade of Vaccines

Auteur: Kelly Healy, Heather Ignatius, Erin Fry Sosne

Vaccine Rotavirus supplement

Auteur: Fatima Serhan, Jacqueline E. Tate, Patrick Zuber, Umesh D. Parashar, Adam L. Cohen, Negar Aliabadi

Private Sector COVID-19 Engagement: Cataloguing Activities Around Vaccine Acceptance and Uptake

Auteur: USAID MOMENTUM

Mucosal vaccines for biodefense

Auteur: L. A. Morici, N. J. Mantis, C. J. Roy

KN2 Research for Universal Health Coverage; Perspective on Vaccines and Poverty Reduction

Auteur: Tim Evans, Margaret Chan

Bottlenecks and breakthroughs: Lessons learned from new vaccine introductions in low-resource countries, 2008 to 2013

Auteur: USAID, Maternal Child Health Integrated Program (MCHIP)

P1-4 IA2030 Strategic Priority 7: Research & Innovation. Overview and goals

Auteur: Kwaku Poku Asante

Update on Vaccine-Derived Polioviruses - Worldwide, January 2015-May 2016

Auteur: Ousmane M. Diop, Jaume Jorba, Cara C. Burns, Steven G. Wassilak, Roland W. Sutter, Jane Iber

Zambia_Génération de la Demande Ascendante_FR

Auteur: Covid-19 Vaccine Delivery Partnership

W8 Systems Vaccinology

Auteur: Chair Ingileif Jonsdottir (University Hospital of Iceland)

The global burden of disease generating evidence, guiding policy in Kenya

Auteur: International Centre for Humanitarian Affairs (ICHA), The Institute for Health Metrics and Evaluation (IHME), Kenya Ministry of Health, Kenya Red Cross

Operational Framework for Demand Promotion - Integration

Auteur: World Health Organization (WHO), UNICEF

Addis Declaration on Immunization

Auteur: African Ministers of Health

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition

Auteur: GBD 2013

Will the Decade of Vaccines mean business as usual?

Auteur: Helen Reesemail, Shabir A Madhi

"A wild and wondrous ride": CDC field epidemiologists in the east Pakistan smallpox and cholera epidemics of 1958

Auteur: Paul Greenough

W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programs

Auteur: Fred Were

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

Auteur: GBD 2015

Raising the standard: the Multilateral Development Review 2016

Auteur: Department for International Development, United Kingdom

Manufacturing costs of HPV vaccines for developing countries

Auteur: Yapei Zhang, Rebecca N. Warburton, Donald W. Light, Chaevia Clendinen

Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data

Auteur: Laura V. Cooper, André Bita, Carol Tevi-Benissan, Caroline L. Trotter, Clement Lingani, Katya Fernandez

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region

Auteur: Bartholomew Dicky Akanmori, Dah Cheikh, Carol Tevi-Benissan, Richard Mihigo, Messeret Eshetu, Joseph Okeibunor, Blanche-Philomene Anya, Gaël Maufras du Châtellier, Halima Dao, Afework Assefa, Yusuf Nasir, Joseph Nsiari-Muzenyi Biey

Performance-based financing: just a donor fad or a catalyst towards comprehensive health-care reform

Auteur: Agnès Soucat, Claude Sekabaraga, Bruno Meessen

W2.1 Nucleic acid vaccines: Is it all done?

Auteur: Christian Mandl

Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines

Auteur: Clarissa R Damaso

W4 Controlled Human Infection Models for Vaccine Research and Development

Auteur: Annie Mo, Gagandeep Kang

W1 Innovations in Vaccine Manufacturing

Auteur: Rajat Goyal, Antu Dey

W3 Innovation in Vaccination

Auteur: Bernhards Ogutu, Chair David Durrheim

P3 Shaping the Future: Equitable Access for All

Auteur: Robin Nandy, Daniel Feikin

P1 Epidemic and Pandemic Preparedness and Response

Auteur: George F. Gao, Helen Rees

P7 Optimizing vaccine regimens

Auteur: Andrew Pollard, Kristen Earle

W2 Comprehensive assessment of risks and benefits of vaccines: the example of Dengue

Auteur: Stephen Thomas, Lucky Slamet

W6 Innovation in vaccine delivery and presentation: How can technological advances increase program performance?

Auteur: R. Lagos, M. Gottlieb

P7 Innovative vaccine research: the point of view of industry and biotech companies

Auteur: Odile Leroy, Michael Mowatt

W7 Contributions of Regulatory Science to Vaccine Access

Auteur: Helen Rees, Norman Baylor

P4 Preparing for the next Infectious Disease Emergency

Auteur: Helen Rees, Norman Baylor

P2 HIV, TB & Malaria Vaccine Update

Auteur: Norman Baylor, Lucky Slamet

P5 Evidence for Decision Making

Auteur: Robert Breiman, David Kaslow

W1 - Immunological and Vaccine Considerations for Special Populations: women of reproductive age and pregnancy, people living with HIV, and older adults

Auteur: Ruth Karron, Carolyn Deal

P3 - Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines (and reports from Workshops 1-3)

Auteur: Jerome Kim, Annie Mo

W5 - Vaccine development strategies at the intersection of market model, value drivers, and access policy

Auteur: Raman Rao, Jessica Martinez

W7 - New vaccines on the horizon

Auteur: Alejandro Cravioto, Shahida Baqar

W8 - Select poster highlights

Auteur: Peter Dull, Sinead Delany-Moretlwe

W2 - Novel vaccine platforms

Auteur: Max Silverman, Sue Ann Clemens

W5 New and Improved Vaccines on the Horizon

Auteur: Kathleen Neuzil

P3 Evolving Global Vaccine Markets

Auteur: A. Batson

P6 Polio Endgame: Needs and Opportunities

Auteur: Roland Sutter

Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines

Auteur: Ina U. Park, Eileen F. Dunne, Camille Introcaso

W8 Prioritization for Vaccine R&D

Auteur: Peter Hotez, Jerome Kim, B. T. Slingsby

W8.1 Decision-making and prioritization of vaccines to address public health needs in LMICs

Auteur: Bill Hausdorff

The drug and vaccine landscape for neglected diseases (2000—11): a systematic assessment

Auteur: Bernard Pécoul, Patrice Trouiller, Nathan Ford, Piero Olliaro, Claudette Some, Nathalie Strub-Wourgaft, Jean-Hervé Bradol, Belen Pedrique

Hepatitis vaccines

Auteur: Kathleen B. Schwarz, Sina Ogholikhan

W7.1 Protection of newborn infants through vaccination

Auteur: Tobias Kollmann

Home-based record (HBR) ownership and use of HBR recording fields in selected Kenyan communities: Results from the Kenya Missed Opportunities for Vaccination Assessment

Auteur: Stephanie Shendale, Ikechukwu Udo OGBUANU, Kibet Sergon, Iheoma Ukachi Onuekwusi, Collins TABU, Peter Okoth, David W. Brown, Zorodzai Machekanyanga, Isaac Mugoya

KN3-1 The Importance of Innovation in Addressing Global Health Gaps in the Developing World

Auteur: Trevor Mundel

KN3 Importance of Innovation in Addressing Global Health Gaps in the Developing World

Auteur: Trevor Mundel

W5.4 Improved vaccines: Novel oral polio vaccine (OPV)

Auteur: Ananda S. Bandyopadhyay

P1 From GVAP to IA2030: roles of vaccine R&D to enable success

Auteur: Chair: Lee Hall

World malaria report 2022

Auteur: World Health Organization (WHO)

Keynote 2 - Future Pandemic R&D Preparedness in Korea and Translating Pandemic R&D Learnings into the Broader Global Health Agenda

Auteur: Heechang Jang, NIH Korea; Jerome Kim, IVI

P8 - Reflections and closing remarks: Progress and the path forward

Auteur: Chair: Noni MacDonald, Dalhousie U.

GVIRF 2023 Welcome and Opening Remarks

Auteur: Chair: Lee Hall

P5 - Innovating to find and reach Zero-Dose Children

Auteur: Chair: Samir Sodha, WHO

Keynote 1 - Vaccines in the Post-COVID Era: Can Policy and Practice Keep up with Science

Auteur: Barney Graham

P2 - Lessons from COVID-19 vaccines and future pandemic preparedness

Auteur: Chair: Charlie Weller, Wellcome

P5-3 Using mHealth Interventions to Improve Vaccination Coverage

Auteur: Abdul Momin Kazi

P6 - Vaccine technologies for equity

Auteur: Chair: Philippe-Alexandre Gilbert, BMGF

W4 - Mucosal immunity and vaccines

Auteur: Chair: Melanie Saville, CEPI

W3 - Regional manufacturing

Auteur: Chair: Martin Friede, WHO

Rwanda - Digital Solutions for COVID-19 vaccination

Auteur: MoH Rwanda

P6-3 A low footprint vaccine manufacturing platform for in-country, for-country production

Auteur: Mathias Garny

P5-4 Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approach

Auteur: Melkamu Ayalew

Agenda - GVIRF 2023 - PRINTABLE

Auteur: GVIRF Secretariat

W8-9 Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariants

Auteur: Chang-Yuil Kang

W8-8 The landscape of infectious disease exposure over the past two decades in the Kenyan coast

Auteur: Timothy Chege

W8-7 RV 460 Study: Comparative Adjuvant Study or HIV Env-C DNA and Protein Vaccines in Kenya

Auteur: Josphat Kiprop Kosgei

W8-6 Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse Model

Auteur: Chul Kim

W8-4 Innovative DDS "DegradaBALL" for mRNA vaccine against next pandemics: "100 days mission"

Auteur: Dal-Hee Min

W8-5 Cross-neutralization of Influenza A by SARS-CoV-2 antibodies

Auteur: Mohammad Mamun Alam

W8-3 High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in Ethiopia

Auteur: Debasu Damtie

W8-2 Changing the HPV Landscape with Indigenous Vaccine: CERVAVAC

Auteur: Hitt Sharma

W8-1 Workshop 8: Select Poster Highlights

Auteur: Peter Dull

W7-4 Enteric Disease: Shigella and ETEC Vaccine Development

Auteur: Michelo Simuyandi

W7-3 2023: the year of RSV

Auteur: Ruth Karron

W7-2 Dengue Vaccines

Auteur: Annelies Wilder-Smith

W6-5 Protecting young infants through immunoprevention

Auteur: Jessica Fleming

W6-4 Reaching adolescent girls with the HPV vaccine

Auteur: Cathy Ndiaye

W6-3 Implementation research needs on vaccine delivery according to epidemiological context

Auteur: Halidou Tinto

W6-1 What is implementation research and why is it important?

Auteur: Alexander Rowe

W5-5 Developing vaccines as global public good: RIGHT foundation’s approach

Auteur: Hani Kim

W5-4 The Next Frontier in Defining Value: Health Economics in LMICs

Auteur: Alice Chen

W4-6 A translational Research Institute focused on vaccines and airway immunity

Auteur: Peter Andersen

W4-5 mRNA-lipid nanoparticle vaccines for intranasal delivery

Auteur: Darin Edwards

W4-4 Adenovirus Vector Based Covid-19 Inhalation Vaccine

Auteur: Chunlin Xin

W4-3 A Mucosally-delivered Newcastle Disease Virus-vectored Booster Vaccine to Prevent SARS-CoV-2 Breakthrough Infection and Transmission

Auteur: Michael Egan

W4-2 Mucosal Immunity: What’s special about it and can vaccines induce it?

Auteur: Peter Openshaw

W4-1 Mucosal Immunity: Opening Remarks

Auteur: Melanie Saville

W3-5 The case for globally distributed vaccine manufacturing - CEPI perspective

Auteur: Melanie Saville

W2-3 mRNA and adjuvants friends…or foes ?

Auteur: Nathalie Garcon

W3-4 Gavi’s Strategy to Support Regional Manufacturing

Auteur: Marta Tufet

W3-3 Biological E. Limited

Auteur: Mahima Datla

W3-2 An African Mission - Establish and Sustain

Auteur: Patrick Tippoo

W2-5 New Developments in Viral Vector Vaccines

Auteur: Jerry Sadoff

W2-4 Nanoparticle Vaccines: A success story for viral vaccine development

Auteur: Harry Kleanthous

W1-5 COVID 19 vaccine effectiveness in the elderly population

Auteur: Tarun Saluja

W1-4 TB Vaccine Roadmap for People Living with HIV

Auteur: Mindy Miner

W1-3 Group B Streptococcus Vaccination in Pregnant Women

Auteur: Anna Seale

W1-2 Vaccines for special populations: Immunological considerations

Auteur: Arnaud Didierlaurent

P7-5 Timing of South Africa's PCV and Measles infant doses: considerations on the adoption of a vaccine schedule

Auteur: Rudzani Muloiwa

P7-4 Optimizing vaccine regimens – HPV Vaccines

Auteur: Deborah Watson-Jones

P7-3 Impact on immunogenicity: Dose, Schedule and Platform

Auteur: Andrew Pollard

P7-2 Optimizing immunization schedules

Auteur: Naor Bar-Zeev

P7-1 GVIRF Plenary 7: Optimizing vaccine regimens

Auteur: Kristen Earle

P6-5 EuBiologics’s Vaccine Technologies for Equity

Auteur: Rachel Park

P6-4 Single Injection Vaccines

Auteur: Ana Jaklenec

P6-2 The Vaccine Innovation Prioritisation Strategy (VIPS): driving innovations to improve vaccine delivery in low- and middle-income countries

Auteur: Jean-Pierre Amorij

W9-4 Use of Social data to inform programmatic action for COVID-19 vaccine uptake in Nigeria

Auteur: Hadley Ikwe

W9-3 Applying Social Science & Behavioural Design in Development and Humanitarian settings: Middle East & North Africa

Auteur: Amaya Gillespie

W9-2 Vaccine uptake and equity: How to understand and address low uptake

Auteur: Julie Leask

W9-1 Understanding and addressing behavioural and social drivers

Auteur: Lisa Menning

P5-2 Mapping the distribution of zero-dose children and their characteristics in low- and middle-income countries

Auteur: C. Edson Utazi

P5-1 Introduction to Zero-Dose

Auteur: Samir Sodha

P4-4 A Pathway to Impact: Exploring the potential of measles rubella microarray patches to reach zero dose children and improve measles vaccine coverage through an initial Full Value Vaccine Assessment

Auteur: Jean-Pierre Amorij

P4-3 The Full Vacccine Accessment for Group A Streptococcus Vaccines

Auteur: David Bloom

P4-2 Using the FVVA framework to estimate the potential health and economic impacts of novel TB vaccines in low- and middle-income countries

Auteur: Richard White

P4-1 The Full Value of Vaccines Assessment (FVVA) concept

Auteur: Mark Jit

P3-5 Current Status of Universal Influenza Vaccine Research and Development

Auteur: Punnee Pitisuttithum

P3-4 HIV Vaccine Update

Auteur: Shan Lu

P3-3 Tuberculosis Vaccine R&D

Auteur: Mark Hatherill

P3-1 Introduction: Current status of vaccine R&D for HIV, Tb, Malaria, and Universal flu

Auteur: Annie Mo

KN1 Vaccines in the post-COVID era: Can policy and practice keep up with science?

Auteur: Barney Graham

P2-5 Lessons learned from an industry R&D perspective

Auteur: Tonya Villafana

P2-4 Regulatory Perspective: Brazil

Auteur: Gustavo Santos

P2-3 CEPI's Lessons Learnt from COVID-19 pandemic response and the 100 day mission for pandemic preparedness

Auteur: Melanie Saville

P2-2 Research & innovation: Outbreaks preparedness & response

Auteur: Ana Maria Henao Restrepo

P1-5 Partnering with regions and countries to identify priority pathogens for vaccines

Auteur: Birgitte Giersing

P1-3 Looking Ahead – Themes that will influence the R&D agenda

Auteur: Helen Matzger

P1-1 Overview of GVAP and IA2030

Auteur: Lee Hall

P1-2 Lessons Learned from the Global Vaccine Action Plan

Auteur: Noni MacDonald

KN2-2 Translating pandemic R&D learnings into the broader global health agenda

Auteur: Jerome Kim

KN2-1 Future Pandemic R&D Preparedness in Korea

Auteur: Hee-Chang Jang

Welcome & Opening remarks

Auteur: Lee Hall

GVIRF 2023 Poster Abstracts

Auteur: GVIRF Secretariat

Nepal_Gestion des Déchets COVID-19_Kathmandu Valley

Auteur: WHO Nepal, HECAF360

cPIE_COVID-19 Vaccination Program Post Introduction Evaluation_Lebanon

Auteur: Republic of Lebanon

Immunization Agenda 2030: A Global Strategy to Leave No One Behind

Auteur: IA2030 Partnership

Country experiences with COVID-19 vaccination: Quick Reference Guide - update JANUARY 2023

Auteur: MM Global Health Consulting (MMGH)

The EVM2 Process

Auteur: World Health Organization (WHO), UNICEF

EVM Assessor - Introduction

Auteur: UNICEF, World Health Organization (WHO)

EVM Assessor - Field Guide

Auteur: UNICEF, World Health Organization (WHO)

*Meeting Summary: Global Vaccine and Immunization Research Forum, 2021

Auteur: Andrew Ford

COVAX - Key Learnings for Future Preparedness Pandemic & Response

Auteur: COVAX

COVAX - Key Learnings for Future PPR_Sept 2022 - FINAL

Auteur: COVAX

Experiences des pays en matiere de vaccination COVID-19 - version Sept 2022

Auteur: MM Global Health Consulting (MMGH)

Country experiences with COVID-19 vaccination: Quick Reference Guide - update September 2022

Auteur: MM Global Health Consulting (MMGH)

Global NITAG Network

Auteur: Global NITAG Network

Partnering with regions and countries to identify priority pathogens for vaccines: Update to PDVAC, 5 December 2022

Auteur: Vaccine Prioritization & Platforms Team

Verification and Traceability Iniative - Reflections from the Past Year

Auteur: Verification and Traceability Initiative

W11 Vaccine Hesitancy

Auteur: Narendra Arora

KN3 Research for Equity - VIDEO

Auteur: Soumya Swaminathan

2022-10-12 Correlates of Protection - VIDEO

Auteur: GVIRF Secretariat

2022-06-23 Vaccines as Tools to Prevent Antimicrobial Resistance: Advances, challenges, and future development - WEBINAR ANNOUNCEMENT

Auteur: GVIRF Secretariat

2022-03-03 Malaria Vaccine R&D and Immunization Lessons Learned and Considerations for Global Health Impact - VIDEO

Auteur: GVIRF Secretariat

2022-06-23 AMR: Vaccines as Tools to Prevent Antimicrobial Resistance: Advances, challenges, and future development - AGENDA

Auteur: GVIRF Secretariat

2022-06-23 AMR: Vaccines as Tools to Prevent Antimicrobial Resistance - VIDEO

Auteur: GVIRF Secretariat

2022-06-23 AMR: Les vaccins comme outils de prévention de la RAM - VIDEO

Auteur: GVIRF Secretariat

2022-06-23 AMR: Las vacunas como herramientas para prevenir la RAM - VIDEO

Auteur: GVIRF Secretariat

COVAX: Structures and Principles

Auteur: COVAX

Global Vaccine Market Report 2022

Auteur: World Health Organization (WHO)

YF testing algorithm

Auteur: EYE Strategy Laboratory Technical Working group (EYE-LTWG)

RDT IgM Arbo panel interpretation

Auteur: EYE Strategy Laboratory Technical Working group (EYE-LTWG)

List of GYFLaN members

Auteur: EYE Strategy Laboratory Technical Working group (EYE-LTWG)

EQA technical report for serological testing of YF

Auteur: EYE Strategy Laboratory Technical Working group (EYE-LTWG)

Standard operating procedure for shipping yellow fever (YF) specimens to Regional Reference Laboratories (RRLs)

Auteur: Hazgo, World Health Organization (WHO)

Compilation for job aids for laboratory confirmation

Auteur: United Republic of Tanzania Ministry of Health

Decade of Vaccines. Foreword.

Auteur: Seth Berkley, Joy Phumaphi, Anthony Lake, Anthony Fauci, Christopher Elias, Margaret Chan

P1.3 Rapid (and precise) COVID-19 Vaccine Development Enabled by Prototype Pathogen Preparedness

Auteur: Barney S. Graham

P6.1 Universal Influenza Vaccine Development

Auteur: Barney S. Graham

W3 Total Systems Effectiveness

Auteur: Carsten Mantel, James Goodson, Tina Lorenson, Melissa Malhame, Darin Zehrung, Mercy Mvundura, Jean-Pierre Amorij, Messeret Shibeshi

W6 Vaccine Development to Access

Auteur: Narendra Arora, Alejandro Cravioto, Ian Hudson, David Kaslow, Joshua Chu, Rino Rappuoli, Sai Prasad, Birgitte Giersing, Deepali Pate

W2 Emerging Platforms

Auteur: Lynda Stuart, Kanta Subbarao, Florian Krammer, Nathalie Garcon, Sarah Gilbert, Christian Mandl

P1b Develop New and Improved Vaccines - TB

Auteur: Charles Mgone, Tom Evans, Uli Fruth

P1c Develop New and Improved Vaccines - Malaria

Auteur: Peter Smith, Ashley Birkett, Charles Mgone

Overview of Gavi Full Country Evaluations Findings

Auteur: Universidade Eduardo Mondlane, Health Alliance International, Gavi, the Vaccine Alliance, PATH, University of Zambia, Infectious Diseases Research Collaboration (IDRC)

W2 R&D Update: Enteric Vaccines

Auteur: Jean-Pierre Amorij, Gagandeep Kang

The power of straight talk

Auteur: Nellie Bristol, Chris Millard

KN2.2 Innovating from Research to Impact at Scale: the role of the Gavi Alliance

Auteur: Anuradha Gupta

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

Auteur: Anthony Fauci

KN1.1 Vaccine Research and Development: Challenges and Opportunities

Auteur: Anthony Fauci

KN1 Opening Session and Keynote

Auteur: Anthony Fauci

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

Auteur: Anthony Fauci

P2.2 Update on progress in tuberculosis vaccine development

Auteur: Ann Ginsberg

Introduction to GVIRF

Auteur: B. Fenton Hall

*Meeting report: Global vaccine and immunization research forum, 2018

Auteur: Peter Dull, Martin Friede, B. Fenton Hall, Angela Hwang

Context and Purpose of GVIRF

Auteur: Thomas Cherian

KN1.2 R&D in the "Decade of Vaccines"

Auteur: B. Fenton Hall

*Meeting report: Global vaccine and immunization research forum

Auteur: Angela Hwang, Andrew Ford, Nancy Touchette, Joachim Hombach, B. Fenton Hall

*Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery

Auteur: Angela Hwang, Andrew Ford, Nancy Touchette, Joachim Hombach, B. Fenton Hall

Introduction to GVIRF

Auteur: B. Fenton Hall

P8 General Conclusion

Auteur: Chris Wilson, Jean-Marie Okwo-Bele, B. Fenton Hall

W4.2 Typhoid controlled human infection model

Auteur: Andrew Pollard

W4.2 Immunological Challenges in vaccination and vaccine development

Auteur: Andrew Pollard

W9.3 Building and Sustaining Uptake: Case study the Philippines

Auteur: Anna Ong-Lim

P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemic

Auteur: Ana Maria Henao Restrepo

W1.2 Vaccine Manufacturing at Lab Scale: A paradigm shift to more affordable vaccines

Auteur: Ahd Hamidi

W5.3 Single-dose HPV Vaccination

Auteur: Aimee R. Kreimer

Vaccine R&D Priorities: Initial Landscaping and Proposed Methods

Auteur: Vaccine Prioritization & Platforms Team

Partnering with regions and countries to identify priority pathogens for vaccines

Auteur: Vaccine Prioritization & Platforms Team

Holding the World to Account COVID GAP

Auteur: Duke University and COVID Collaborative

Assessing Country Readiness for COVID-19 vaccines

Auteur: World Bank

USAID's Covid-19 response: Fact sheets

Auteur: USAID

BMGF_Prepare to Respond Learning Forum

Auteur: Bill & Melinda Gates Foundation

JHPIEGO_COVID-19 Response Expertise

Auteur: Jhpiego

JHU_Report Series: a primer on COVID-19 vaccine development, allocation and deployment

Auteur: Johns Hopkins University

World Bank_Feature Stories on COVID-19 response

Auteur: World Bank

Gavi_Demand Promotion a Community Engagement

Auteur: Gavi, the Vaccine Alliance

From epidemic meningitis vaccines for Africa to the Meningitis Vaccine Project

Auteur: M. Teresa Aguado et al.

Fulfilling a promise: ensuring immunization for all in AFRICA

Auteur: World Health Organization (WHO)

P6 Protection of pregnant women, neonates and infants by maternal immunization

Auteur: Helen Rees

P5 Research to improve monitoring and evaluation of immunization programs

Auteur: Jean-Marie Okwo-Bele

P3 Developing Next Generation Vaccines: Defining the Improvements Needed and Evaluating Their Potential

Auteur: Chair K. Neuzil

P2 Regulatory and Public Health Challenges for Vaccines Inducing Modest Efficacy

Auteur: David Salisbury

Agenda - GVIRF 2014

Auteur: GVIRF Secretariat

W9.3 Maternal influenza vaccines: How has the VIS process influenced the research agenda

Auteur: Saad Omer

W9.2 What’s Next for Gavi's Vaccine Investment Strategy: Rabies

Auteur: Bernadette Abela-Ridder

W9.1 How does Gavi make vaccine investment decisions?

Auteur: Judith Kallenberg

W8.3 Combination Vaccines: Benefits and Risks

Auteur: Melissa Malhame

W8.2 Combination Vaccines: Potential future states

Auteur: Peter Dull

W8.1 Combination Vaccines: How and Why? Lessons Learned

Auteur: Michel De Wilde

W7.3 Intestinal Microbiota and Enteric Vaccine Design

Auteur: James Fleckenstein

W7.2 The Nasal Microbiota: Diversity, Dynamicity, and Vaccine-mediated Effects

Auteur: Jane Deng

W7.1 The infant microbiome: Relevance to immune responses

Auteur: María Gloria Domínguez-Bello

W8.3 Application of technological advances to clinical trials

Auteur: Willem Hanekom

W8.2 Systems Vaccinology

Auteur: Bali Pulendran

W8.1 How can recent technological advances in systems vaccinology accelerate next-generation vaccine development?

Auteur: Chair Ingileif Jonsdottir (University Hospital of Iceland)

W7.3 How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?

Auteur: Marion Gruber

W7.2 Enhancement in Laboratory Research to Support Innovations in Regulatory Science for the Evaluation of New Vaccines

Auteur: Teeranart Jivapaisarnpong

W7.1 Contributions of Regulatory Science to Vaccine Access

Auteur: Norman W. Baylor

W6.3 Case Study: The Uniject Injection System

Auteur: Debra Kristensen

W6.2 Beyond the cold chain… Meningitis A conjugate vaccine in a controlled temperature chain: Experience from Benin

Auteur: Olivier Ronveaux

W6.1 WHO - Next-generation Vaccine Delivery Technology Meeting Summary

Auteur: Darin Zehrung

W5.4 Building Implementation Research Capacity for Polio Eradication

Auteur: Margaret Gyapong

W5.3 Strengthening national capacity for evidence-based immunization policy: the case of program costing in Honduras

Auteur: Cara Bess Janusz

W5.2 Factors influencing community health volunteers in participating in health programs in Africa

Auteur: Fadima YAYA BOCOUM

W5.1 Immunization implementation research priority setting

Auteur: John Clemens

W4.2 Prioritizing the Research Agenda for Measles and Rubella

Auteur: William Moss

W4.1 Progress, Challenges, and Lessons Learned in Achieving Measles and Rubella Goals

Auteur: Thomas Cherian

W3.2 Pre-exposure rabies vaccination (PreP) in children of endemic countries

Auteur: D. Briggs

W3.1 Leishmania Vaccine Development: Progress and challenges in the context of other control strategies

Auteur: Farrokh Modabber

W2.3 Group A streptococcal vaccines: Challenges and progress

Auteur: Florian Schödel

W2.2 RSV Vaccine Development for Low and Middle Income Countries: Challenges and Progress

Auteur: Claudio Lanata

W2.1 WHO Preferred Product Characteristics: Bridging Vaccine R&D with Public Health

Auteur: Vasee Moorthy

W1.1 Towards the Development of a Universal Influenza Vaccine

Auteur: David Spiro

P7.1 Innovation for vaccines against poverty diseases: the need for new support mechanisms

Auteur: Martin Friede

P6.2 Maternal Immunization: which impact on infant immunity?

Auteur: Claire-Anne Siegrist

P6.1 Public Health Benefits of Maternal Immunization

Auteur: Keith Klugman

P5.2 Influenza Vaccine Use in the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-1

Auteur: Alba Maria Ropero-Alvarez

P5.1 Immunization Registries in Latin America and the Caribbean

Auteur: M. Carolina Danovaro-Holliday

P3.4 Evaluation of the Next Generation of Rotavirus Vaccines

Auteur: Kathleen Neuzil

P3.3 Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health Needs

Auteur: Mary K. Estes

P3.2 Developing Country Vaccine Manufacturers - Access to Immunization

Auteur: Umesh Parashar

P3.1 Developing next generation vaccines: Introduction

Auteur: Kathleen Neuzil

P2.2 Regulatory Considerations for Determining Vaccine Efficacy

Auteur: Marion Gruber

P2.1 Regulatory and public health challenges

Auteur: Peter Smith

P1c.2 Progress towards the development of a malaria vaccine: discussion

Auteur: Peter Smith

P1c.1 Progress towards the development of a malaria vaccine

Auteur: Ashley Birkett

P1b.2 TB Vaccine Development: Challenges & Opportunities

Auteur: Uli Fruth

P1b.1 Update on Tuberculosis Vaccines - 2014

Auteur: Tom Evans

P1a.2 Progress towards the development of an HIV vaccine: Discussion

Auteur: José Esparza

P1a.1 Status of HIV Vaccine Research & Development

Auteur: Wayne Koff

KN2.2 Perspectives on Vaccines and Poverty Reduction

Auteur: T. Evans, World Bank

KN2.1 WHO Director-General address to GVIRF

Auteur: Margaret Chan

KN1.4 What do we expect from the meeting?

Auteur: José Esparza

KN1.3 GVIRF Overview and Goals

Auteur: Joachim Hombach

W4 How to Optimize Immunization Coverage? A case study from Measles-Rubella vaccination

Auteur: A. A. Adeyemo

W2 Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health Utility

Auteur: A. A. Adeyemo

W1 Towards the Development of a Universal Influenza Vaccine

Auteur: David Spiro

W6.4 Second year of life platform and monitoring systems

Auteur: Jan Grevendonk

W6.3 Protecting Lives in the 2nd Year of Life (2YL) in Ghana

Auteur: Abigail Shefer

W6.2 Raising the Profile of an 18-month Well-child Visit: the 2YL Platform

Auteur: Elicah Kandinda Kamiji

W6.1 Global landscape analysis and literature review of 2nd year of life immunization platform

Auteur: Imran Mirza

W6.0 Intro: Establishing a Second-year-of-life (2YL) Healthy Child Visit

Auteur: Rudi Eggers

W6 Immunization in the Second Year of Life

Auteur: Rebecca Fields

W5.3 Good Participatory Practices for Vaccine Clinical Trials

Auteur: Nelson Michael

W5.2 African Vaccine Regulatory Forum (AVAREF): New Vision and Blueprint for Ethics and Regulatory Capacity Strengthening in Africa

Auteur: Dicky Akanmori

W5.1 WHO Regulatory Strengthening Update & LMICs Challenges in Vaccine Clinical Trial Regulation

Auteur: William Wekwete

W5 Regulatory Challenges and Constraints When Evaluating Vaccine Clinical Trials

Auteur: Chair Klaus Cichutek

W4.6 Vaccines for healthcare pathogens: No ESKAPE

Auteur: Jordi Rello

W4.5 Gonococcal antimicrobial resistance and vaccines

Auteur: Magnus Unemo

W4.4 Vaccines to prevent antibiotic-resistant Staphylococcus aureus (MRSA) infections

Auteur: Olaf Schneewind

W4.3 The Role of Vaccines in Antimicrobial Resistance Strategies

Auteur: Bruce Gellin

W4.2 WHO Global Action Plan on Antimicrobial Resistance

Auteur: Martin Friede

W4.1 Introduction: Antimicrobial Resistance & Vaccines

Auteur: A. A. Adeyemo

W3.4 Vaccine technology costs and health impact assessment tool

Auteur: Mercy Mvundura

W3.3 Microarray patch case study: Measles-rubella vaccine

Auteur: Darin Zehrung

W3.2 Total System Effectiveness

Auteur: Tina Lorenson

W3.1 Introduction: Total Systems Effectiveness

Auteur: Tina Lorenson

W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk Management

Auteur: Peter Smith

W11.4 Applying TIP to low and middle income settings: a case study from South Africa

Auteur: Nicola Christofides and Janine Simon-Meyer

W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in Sweden

Auteur: Ann Lindstrand

W11.2 Vaccine Hesitancy: Determining the scale of the challenge

Auteur: Susan Goldstein

W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle it

Auteur: Robb Butler

W10.4 Rabies antibodies for Passive Post-exposure prophylaxis

Auteur: Tsepo Tsekoa

W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV Prevention

Auteur: Wayne Koff

W10.2 Passive vaccination as a global strategy for preventing RSV disease in infants

Auteur: Filip Dubovsky

W10.1 Monoclonal antibodies for infectious diseases

Auteur: Martin Friede

W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffolds

Auteur: Neil King

W1.2 Epitope-focused vaccine design

Auteur: Bill Schief

W1.1 Structural studies of viral envelope proteins and insights for vaccine design

Auteur: Felix Rey

W1.0 Introduction: Applying Novel Technologies to Vaccine Development

Auteur: Rino Rappuoli

W9.4 Antibody Engineering: Optimization of Antibodies for Commercialization

Auteur: Stephen Hadley

W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen Design

Auteur: Bruce Innis

W9.2 Monoclonal antibodies for rabies post-exposure prophylaxis

Auteur: Erin Sparrow

W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIV

Auteur: Barney Graham

W8.3 The Principle and Process of Autogenous Vaccine

Auteur: Suphot Wattanaphansak

W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicability

Auteur: Edgar Brun

W8.1 Antimicrobial Resistance and Vaccines

Auteur: Dennis Dixon

W7.5 Target Value Proposition

Auteur: Jean Lang

W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returns

Auteur: Maria Elena Bottazzi

W7.3 A Hepatitis C Virus Vaccine Update

Auteur: Andrea Cox

W7.2 Update on RSV Vaccine and mAb development

Auteur: Ruth Karron

W7.1 Global Vaccine Pipeline and Value Proposition

Auteur: David Kaslow

W6.3 Maternal and adolescents immunization - a global challenge

Auteur: Raymond Hutubessy

W6.2 Adolescent Immunization in Developing Countries: Obstacles and Opportunities

Auteur: Hartono Gunardi

W9 Gavi's Vaccine Investment Strategy (VIS)

Auteur: Helen Rees

W8 Combination Vaccines: Why and How?

Auteur: A. A. Adeyemo

P6.4 Preferred Product Characteristics

Auteur: David Kaslow

P6.3 Schistosomiasis Vaccine Updates

Auteur: Annie Mo

P6.2 Vaccine development for Group A Streptococcus

Auteur: Andrew Steer

P5.4 An emerging vaccine delivery technology for measles and rubella elimination

Auteur: James Goodson

P5.3 Measles and Rubella Research Agenda

Auteur: Narendra K Arora

P5.2 The Investment Case for Measles Eradication

Auteur: Kimberly Thompson

P5.1 What are the measles vaccination coverage gaps?

Auteur: Peter Strebel

P5 New Technologies to Support Measles Elimination

Auteur: A. A. Adeyemo

P4.3 Regulatory Preparedness for the Next Infectious Disease Emergency

Auteur: Delese Mimi Darko

P4.2 Preparing for the Next Infectious Disease Emergency

Auteur: Lucille Blumberg

P4.1 Preparing for the inevitable

Auteur: David Wook

P3.1 Global vaccine market

Auteur: Amie Batson

P2.4 Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures

Auteur: Walter Jaoko

P2.3 Moderate efficacy malaria vaccines as part of comprehensive malaria control and elimination

Auteur: Salim Abdullah

P2.2 Lessons from Rotavirus and Pneumococcal Conjugate Vaccines

Auteur: Katherine L. O'Brien

P2.1 The role of moderate efficacy vaccines in integrated disease control strategies: Introduction

Auteur: Kathleen Neuzil

P2 The role of moderate efficacy vaccines in integrated disease control strategies

Auteur: Katherine L. O'Brien

P1.3b Vaccines for Malaria - Updates on Progress

Auteur: Mahamadou Thera

P1.3a Malaria Vaccines

Auteur: Eusebio Macete

P1.2a TB Vaccine Research and Development: Progress, Strategies and Controversies

Auteur: Lewis Schrager

P1.1b HIV Vaccines: Marry HIV efficacy studies to science, but take shots on goal

Auteur: Nelson Michael

P1.1a RSA & HIV vaccine efficacy studies

Auteur: Glenda Gray

KN3 Vaccine Manufacturing in Africa: Self-sufficiency, a need? Or a dream?

Auteur: William Ampofo

KN1 Opening Session and Dr Margaret Chan Keynote

Auteur: GVIRF Secretariat

W6.1 Reaching Adolescents & Pregnant Women (Introduction)

Auteur: Odile Leroy

W5.4 Universal Influenza Vaccines and Their Role in Preparedness

Auteur: Jennifer Gordon

W5.3 Epidemic Preparedness: National Security for Thailand

Auteur: Punee Pitisuttithum

W5.2 Influenza Pandemic Risk and Preparedness

Auteur: John S. Tam

W5.1 WHO R&D Blueprint Update: progress and Plans

Auteur: Martin Friede

W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protection

Auteur: Christian Ockenhouse

W4.3 New technologies for studying human immunity

Auteur: Lisa Wagar

W4.1 New Approaches to Understanding Human Immunity

Auteur: Annie Mo

W3.3 The Future of Pneumococcal Conjugate Vaccines

Auteur: Keith Klugman

Malaria Vaccine Decision-Making Framework

Partnership for Influenza Vaccine Introduction (PIVI)

Criteria for inclusion of vaccinations in public programmes

Accelerating policy, deployment, and access to new and underutilized vaccines in developing countries

The Grading of Recommendations Assessment, Development and Evaluation (GRADE)

PriorityVax

15th TechNet Conference - Conference Opening

Auteur: Laura Herman, Patrick Lydon, Oleg Benes, Ousmane Dia, Chris Wright, Alan Brooks

15th TechNet-21 Confernece - Collaborative Action for Impact

Auteur: Dmitri Davydov

Una introducción a VIPS (Estrategia de priorización e innovación en vacunas) (16ª Conferencia TechNet)

Auteur: Birgitte Giersing, Marion Menozzi-Arnaud

Sesión plenaria: Apertura de la conferencia (16ª Conferencia TechNet)

Auteur: Robin Nandy, Saada Al Salti, Alex de Jonquieres, Souleymane Kone, Ann Lindstrand, Benjamin Schreiber, Marie Khémesse Ngom Ndiaye

Sesión plenaria: Reapertura de la conferencia (16ª Conferencia TechNet)

Auteur: Sena Kwawu, Adama Sawadogo, Dan Brigden, Diana Chang-Blanc, Peter Okebukola

Introduction à la stratégie de priorisation des innovations en matière de vaccination (VIPS) (16ème Conférence TechNet)

Auteur: Marion Menozzi-Arnaud, Birgitte Giersing

Séance plénière d'ouverture (16ème Conférence TechNet)

Auteur: Benjamin Schreiber, Marie Khémesse Ngom Ndiaye, Robin Nandy, Saada Al Salti, Alex de Jonquieres, Souleymane Kone, Ann Lindstrand

Séance plénière d'ouverture, jour 2 (16ème Conférence TechNet)

Auteur: Diana Chang-Blanc, Peter Okebukola, Sena Kwawu, Adama Sawadogo, Dan Brigden

Cérémonie de clôture en plénière (16ème Conférence TechNet)

Auteur: Karan Sagar, Matt Morio, Souleymane Kone, Adama Sawadogo, Dan Brigden

TechNet Conference opening ceremony (16th TechNet Conference)

Auteur: Marie Khémesse Ngom Ndiaye, Robin Nandy, Saada Al Salti, Alex de Jonquieres, Souleymane Kone, Ann Lindstrand, Benjamin Schreiber

An introduction to VIPS - outcomes of the prioritization process and next steps (16th TechNet Conference) - video

Auteur: Marion Menozzi-Arnaud, Birgitte Giersing

Private sector engagement for COVAX

Auteur: Chris Larson, Maeve Magner, Olivier Defawe

TechNet-21 & the Partnership of Immunization Networks (PIN) (16th TechNet Conference)

Auteur: Sarah Kester, Walter Proper, Alex Pascutto, Dan Brigden, Nathan Pienkowski, Reda Sadki

Conference re-opening (16th TechNet Conference) - video

Auteur: Dan Brigden, Adama Sawadogo, Sena Kwawu, Peter Okebukola, Diana Chang-Blanc

TechNet Conference closing ceremony (16th TechNet Conference)

Auteur: Matt Morio, Souleymane Kone, Adama Sawadogo, Dan Brigden, Karan Sagar

W3.2 Rollout of Pneumococcal Conjugate Vaccine in India

Auteur: Pradeep Haldar, Narendra K Arora

W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and Impact

Auteur: Katherine L. O'Brien

W2.3 Controlled Human Infection Models and Enteric Vaccine Development

Auteur: Beth Kirkpatrick

W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccines

Auteur: Cal MacLennan

W2.1 An update on rotavirus vaccines

Auteur: Gagandeep Kang

W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) Vaccines

Auteur: Kai Dallmeier, Johan Neyts

W1.2 New Vaccine Strategies using cytomegalovirus

Auteur: Klaus Früh

W1.1 MIMIC: an in vitro model of human immunity

Auteur: Don Drake

Programme pour la vaccination à l’horizon 2030. Une stratégie mondiale pour ne laisser personne de côté

Auteur: Organisation Mondiale de la Santé (OMS)

W9 Antibody-Mediated Prevention

Auteur: Chair Nina Russell

W8 Vaccines and Antimicrobial Resistance (AMR)

Auteur: A. A. Adeyemo

W7 New Vaccine Pipeline: Lessons Learned and Accelerating Progress

Auteur: Jean-Pierre Amorij

W6 Reaching Adolescents and Pregnant Women

Auteur: Odile Leroy

W5 Epidemic and Pandemic Preparedness

Auteur: Martin Friede

W4 Immunological Principles of Vaccines and Vaccination

Auteur: Chairs Annie Mo and Bernhards Ogutu

W3 Pneumococcal Vaccines: Lessons Learned and the Road Ahead

Auteur: Hani Kim

W1 Emerging Vaccine Strategies & Technologies

Auteur: Chair Paula Bryant

P7 Discussion with Thought Leaders

Auteur: Peter Dull

P6.5 Research for polio policy making: Lessons learned

Auteur: Roland Sutter

P6.4 Polio Vaccines - R&D Updates

Auteur: Peter Dull

P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?

Auteur: Ondrej Mach

P6.2 Global tOPV withdrawal: "The Switch" experience

Auteur: Alejandro Ramirez Gonzalez

P6.1 Intro Polio Endgame: Needs and Opportunities

Auteur: Roland Sutter

P5.2 Evidence for Decision Making

Auteur: Yot Teerawattananon

P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseases

Auteur: David Kaslow

P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from Thailand

Auteur: Akanid Wapeewuttikorn

P4.2 Benefits and Challenges: How regulators can reduce time and efforts in the case of public health emergencies?

Auteur: Yeowon Sohn

P4.1 Alternative Regulatory Pathways: Opportunities and Challenges

Auteur: Norman W. Baylor

P4 Regulatory Capacity, Challenges, and Convergences

Auteur: Norman W. Baylor

P3.4 Addressing Patent Barriers to Vaccine Development & Access

Auteur: Kate Elder

P3.3 Vaccine Manufacturing in Developing Countries: Perspectives on Approaches to Take, and Factors to Consider, towards Sustainable Manufacturing Capacity

Auteur: Martin Nicholson

[DUPLICATE] P3.2 Developing Country Vaccine Manufacturers - Access to Immunization

Auteur: Lakshminarayana Neti

P3.1 Vaccine Production in Developing Countries: an Economic Evaluation

Auteur: Syarifah Liza Munira

P3 Growing Developing Country Vaccine Manufacture

Auteur: A. A. Adeyemo

P2.6 Strengthening Vaccination Programs among the Urban Poor: Closing the Equity Gap

Auteur: Folake Olayinka

P2.5 Universal Health Coverage: a people-centred approach

Auteur: Birgitte Giersing

P2.4 Social Media Initiative in Ukraine: Analysis of Conversations on Polio, Vaccination and Routine Immunization

Auteur: Anna Postovoitova

P2.3 Innovating for Equity - Kaduna, Nigeria Discussion Paper

Auteur: Muhammad Awwal Waziri

P2.2 Use of Multiple Measures for Immunization Management in Migratory Population

Auteur: Lin Luan

P2.1 Intensified Mission Indradhanush: Addressing Equity in Immunization

Auteur: Pradeep Haldar

P2 Innovating for Equity

Auteur: Narendra Arora

P1.5 Gaps in Malaria Vaccines

Auteur: J. Kevin Baird

P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine development

Auteur: Fred Binka

P1.3 Progress towards vaccines against TB

Auteur: Gerald Voss

P1.2 Commonalities across vaccine development efforts

Auteur: Punnee Pitisuttithum

P1.1 Advanced Clinical Development of HIV Vaccines

Auteur: K. T. Mngadi

P1 Progress Towards and Commonalities in Vaccine Development Against HIV, TB, and Malaria

Auteur: Chair Mary Marovich

KN2 National and regional capacity for biotechnology research; Indian experience

Auteur: Maharaj Kishan Bhan

KN1 Beyond effectiveness: research on vaccines seen as a continuum

Auteur: Alejandro Cravioto

Agenda - GVIRF 2018

Auteur: GVIRF Secretariat

Data Sharing Protocol

Auteur: Verification and Traceability Initiative

Core Principles

Auteur: Verification and Traceability Initiative

Country Deployment Brief

Auteur: Verification and Traceability Initiative

Verification and Traceability Initiative 2 Page Brief

Auteur: Verification and Traceability Initiative

Verification and Traceability Initiative Overview

Auteur: Verification and Traceability Initiative

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

Auteur: World Health Organization (WHO)

Defeating meningitis by 2030: a global road map

Auteur: World Health Organization (WHO)

Vaincre la méningite à l'horizon 2030 une feuille de route mondiale

Auteur: Organisation Mondiale de la Santé (OMS)

W2.3 Adjuvants

Auteur: Nathalie Garcon

Feasibility assessment of measles and rubella eradication

Auteur: Tracey Goodman, William J. Moss, Katrina Kretsinger, Stephanie Shendale, Ann Lindstrand, Katherine L. O'Brien, Nikki Turner

Polio Eradication Strategy 2022-2026: Delivering on a Promise

Auteur: GPEI - Global Polio Eradication Initiative

Powering Vaccine R&D: Opportunities for Transformation

Auteur: The Sabin-Aspen Vaccine Science & Policy Group

ACT now, ACT together 2020-2021 Impact Report

Auteur: World Health Organization (WHO)

KN2 The Lessons of COVID-19 for Vaccine Development

Auteur: Bill & Melinda Gates Foundation

P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030

Auteur: Katherine L. O'Brien

KN3 Research for Equity

Auteur: Soumya Swaminathan

W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questions

Auteur: Julie Leask

W9 Building and Sustaining Uptake

Auteur: Lisa Menning

Agenda - GVIRF 2021

Auteur: GVIRF Secretariat

W6.2 Vaccine development to access: Is there a role for earlier policy consideration?

Auteur: Rino Rappuoli, GSK Vaccines

W5.1 Salmonella typhi vaccines, development and deployment

Auteur: Sushant Sahastrabuddhe, International Vaccine Institute

P3.2 Impact of COVID-19 on coverage and equity

Auteur: Samir Sodha

W5.2 Schistosomiasis vaccines, development and role in elimination

Auteur: Robert Bergquist, Geospatial Health

W4.1 Controlled human malaria infection — tool for accelerating vaccine development

Auteur: Melissa Kapulu, KEMRI-Wellcome Trust Research Programme

P1.2 Rapid Response Platforms for COVID-19 Vaccine

Auteur: Melanie Saville

P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccines

Auteur: Linda-Gail Bekker, University of Cape Town

W2.4 Universal Influenza Vaccines

Auteur: Kanta Subbarao

W1.3 Not enough to go around: vaccine manufacturing for the COVID-19 pandemic

Auteur: Casey Selwyn

W6.3 Building the concept of WHO Vaccine Preferred Policy Profiles

Auteur: Birgitte Giersing

COVAX: The vaccines pillar of the access to COVID-19 tools (ACT) accelerator structure and principles

Auteur: Gavi, the Vaccine Alliance

Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility

Auteur: World Health Organization (WHO)

PAHO Revolving Fund

Auteur: Pan American Health Organization (PAHO)

W6.1 Vaccine Development to Access: Opportunities, risks and potential valleys of death

Auteur: David Kaslow

W9.2 Evidence and Lessons Learned on Social Sciences Analytics around Vaccination

Auteur: Simone Carter, UNICEF

W2.2 Viral vectored vaccine platform technologies

Auteur: Sarah Gilbert, University of Oxford

W3.2 Transformative Concepts for Mass Vaccination and Pandemic Response

Auteur: Matthew Downham, CEPI

W8.2 Prioritization of Vaccines for Global Health

Auteur: Jerome Kim

W8.3 The State of Play: Industry vaccine trends from the Access to Medicine Index

Auteur: Margo Warren, Access to Medicine Foundation

COVID-19 Technical Guidance (04/06/21 update)

Auteur: World Health Organization (WHO)

Shifting towards online training-Possible challenges from Educators/Trainers perspective in Indian setting

Auteur: Lokesh Sharma, Mainak Chattergee, Sumeet Juneja, Paritosh Panigrahi, Snehil Singh, Hitesh Kumar, Prof. Sanjay Gupta, Prof. Harshad Thakur

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Auteur: Heidi J Larson, Yot Teerawattananon, Olivier J Wouters, Mark Jit, Kenneth C Shadlen, Maximilian Salcher-Konrad, Andrew J Pollard

Global Vaccine Market Report - 2020

Auteur: World Health Organization (WHO)

National immunization coverage scorecards estimates for 2019

Auteur: World Health Organization (WHO)

Global vaccine action plan: monitoring, evaluation and accountability. Secretariat annual report 2020

Auteur: World Health Organization (WHO)

Behavioural considerations for acceptance and uptake of COVID-19 vaccines: WHO technical advisory group on behavioural insights and sciences for health

Auteur: World Health Organization (WHO)

TechNet Conference closing ceremony (16th TechNet Conference)

Auteur: Dan Brigden, Souleymane Kone, Matt Morio, Karan Sagar, Adama Sawadogo

Conference re-opening (16th TechNet Conference)

Auteur: Diana Chang-Blanc, Peter Okebukola, Sena Kwawu, Adama Sawadogo, Dan Brigden

TechNet-21 & the Partnership of Immunization Networks (PIN) (16th TechNet Conference)

Auteur: Nathan Pienkowski, Dan Brigden, Alex Pascutto, Walter Proper, Sarah Kester, Reda Sadki

Private sector engagement for COVAX (16th TechNet Conference)

Auteur: Chris Larson, Maeve Magner, Olivier Defawe

TechNet Conference opening ceremony (16th TechNet Conference)

Auteur: Robin Nandy, Marie Khémesse Ngom Ndiaye, Benjamin Schreiber, Ann Lindstrand, Soulemane Kone, Alex de Jonquieres, Saada Al Salti

An introduction to VIPS - outcomes of the prioritization process and next steps (16th TechNet Conference)

Auteur: Marion Menozzi-Arnaud, Birgitte Giersing

TechNet Conference 2020 - Agenda at-a-glance (v20)

Auteur: UNICEF, World Health Organization (WHO)

GVAP secretariat reports, country and regional reports and immunization scorecards

Auteur: World Health Organization (WHO)

The unexpected way that vaccine programmes are stopping children from falling under the radar

Auteur: Jemma L King

Interim guidance for the poliomyelitis (polio) surveillance network in the context of coronavirus disease (COVID-19)

Auteur: World Health Organization (WHO)

Meeting the Challenge of Vaccination Hesitancy

Auteur: The Sabin-Aspen Vaccine Science & Policy Group

Standard precautions for waste management

Auteur: World Health Organization (WHO)

Standard precautions: Hand hygiene

Auteur: World Health Organization (WHO)

COVID-19: How to put on and remove personal protective equipment (PPE)

Auteur: World Health Organization (WHO)

Introduction to Go.Data – Field data collection, chains of transmission and contact follow-up

Auteur: World Health Organization (WHO)

SARI treatment facility design

Auteur: World Health Organization (WHO)

COVID-19 operational planning guidelines and partners platform to support country preparedness and response

Auteur: World Health Organization (WHO)

IPC for COVID-19

Auteur: World Health Organization (WHO)

Health and safety briefing for respiratory diseases – ePROTECT

Auteur: World Health Organization (WHO)

Clinical Management of COVID-19

Auteur: World Health Organization (WHO)

A general introduction to emerging respiratory viruses, including novel coronaviruses

Auteur: World Health Organization (WHO)

Global Vaccine Market Report - 2018

Auteur: World Health Organization (WHO)

WHO Classification of Digital Health Interventions v1.0

Auteur: World Health Organization (WHO)

Vaccination Programs: Standing Orders

Auteur: The Community Guide

Training slides and sample agenda

Auteur: World Health Organization (WHO)

Towards UHC: thinking public - Overview of trends in public expenditure on health (2000-2014)

Auteur: World Health Organization (WHO)

SAGE assessment reports

Auteur: World Health Organization (WHO)

Ending Cholera: A Global Roadmap to 2030

Auteur: Global Task Force on Cholera Control

SOP: Responding to a Poliovirus Outbreak or Event (Parts 1 and 2)

Auteur: GPEI - Global Polio Eradication Initiative

WHO-UNICEF guidelines for developing a comprehensive multi-year plan (cMYP)

Auteur: World Health Organization (WHO), UNICEF

GAPPD: ending preventable child deaths from pneumonia and diarrhoea by 2025

Auteur: World Health Organization (WHO), UNICEF

Immunization Practices Advisory Committee (IPAC) meeting reports

Auteur: World Health Organization (WHO)

Immunization Practices Advisory Committee (IPAC)

Auteur: World Health Organization (WHO)

Developing standardized competencies to strengthen immunization systems and workforce

Auteur: Molly Abbruzzese, Denise Traicoff, Lorraine Shamalla, Carla Lee, Johannes Ahrendts, Tove Ryman, Alice Pope, Jhilmil Bahl, Steven Stewart, Hardeep Sandhu, Peter Bloland, Dharmesh Lal

Introducing the Measles and Measles-Rubella (MR) Vaccine Five-dose vial Presentations

Auteur: World Health Organization (WHO), UNICEF

December 2018 VIEW-hub Report on Global Introduction and Implementation

Auteur: International Vaccine Access Center (IVAC)

Human Resources for Supply Chain Management Theory of Change

Auteur: People That Deliver

September 2018 VIEW-hub Report: Global Vaccine Introduction and Implementation

Auteur: International Vaccine Access Center (IVAC)

Comment élaborer un plan d’amélioration continue (cIP)

Auteur: World Health Organization (WHO), UNICEF

TechNet iSC Submission Guidelines

Auteur: UNICEF

Definition and use of “valid” district level vaccination coverage to monitor Global Vaccine Action Plan (GVAP) achievement: evidence for revisiting the district indicator

Auteur: David W. Brown

Surveillance to track progress toward polio eradication — Worldwide, 2016–2017

Auteur: Tracie J. Gardner et al.

Report from the Seventeenth Meeting Global Commission for the Certification of the Eradication of Poliomyelitis

Auteur: World Health Organization (WHO)

WHOse health agenda? 70 years of struggle over WHO's mandate

Auteur: Anne-Emanuelle Birn

Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary

Auteur: Orenstein WA et al.

Every child alive: The urgent need to end newborn deaths

Auteur: Siobhan Devine et al.

Regional Plan for Containment of Poliovirus in the Americas

Auteur: Pan American Health Organization (PAHO)

Global monitoring of disease outbreak preparedness

Auteur: Harvard Global Health Institute

The polio endgame: securing a world free of all polioviruses

Auteur: Michel Zaffran et al.

New Perspectives on Global Health Spending for Universal Health Coverage

Auteur: Ke Xu et al.

World Malaria Report 2017

Auteur: World Health Organization (WHO)

A Balancing Act: risks and opportunities as polio and its funding disappears

Auteur: Laura Kerr

TechNet Conference 2017 - Slides

Auteur: World Health Organization (WHO)

Pneumonia & Diarrhea Progress Report, 2017

Auteur: International Vaccine Access Center (IVAC)

2017 Assessment Report of the Global Vaccine Action Plan

Auteur: World Health Organization (WHO)

Progress towards regional measles elimination – worldwide, 2000–2016

Auteur: Jean-Marie Okwo-Bele, Minal K Patel, Mick N. Mulders, James L. Goodson, Peter M. Strebel, Paul A. Rota, Marta Gacic-Dobo, Mark J. Papania, Laure Dumolard, Katrina Kretsinger, Alya Dabbagh

Understanding commitment to polio vaccination

Auteur: Kathleen M. O’Reilly

TechNet Conference 2017 - Conference Guide

Auteur: World Health Organization (WHO)

Influenza vaccines: WHO position paper

Auteur: World Health Organization (WHO)

Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio

Auteur: Lee M. Hampton et al.

Monitoring and Validation of the Global Replacement of tOPV with bOPV, April–May 2016

Auteur: Margaret Farrell et al.

Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region

Auteur: Santosh Gurung et al.

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region

Auteur: Sunil Bahl et al.

Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region

Auteur: Kamal Fahmy et al.

Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned

Auteur: Stephanie Shendale et al.

Polio post-certification strategy

Auteur: GPEI - Global Polio Eradication Initiative

June 2017 VIEW-hub Report on Global Introduction and Implementation

Auteur: International Vaccine Access Center (IVAC)

Progress and challenges with achieving universal immunization coverage: 2016 estimates of immunization coverage

Auteur: World Health Organization (WHO), UNICEF

MSF International Activity Report 2016

Auteur: Médecins Sans Frontières (MSF)

Exceptional financial support for introduction of Inactivated Polio Vaccine in middle-income countries

Auteur: Michel J. Zaffran, Anne-Line Blankenhorn, Tania Cernuschi

Communications, immunization, and polio vaccines: Lessons from a global perspective on generating political will, informing decision-making and planning, and engaging local support

Auteur: Lisa Menning et al.

Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the polio endgame

Auteur: Simona Zipursky et al.

Polio endgame: Lessons learned from the Immunization Systems Management Group

Auteur: Simona Zipursky et al.

Шаблон плана развертывания операционной системы

ПЛАТФОРМА ОПТИМИЗАЦИИ ОБОРУДОВАНИЯ ХОЛОДОВОЙ ЦЕПИ

Modèle de plan de déploiement opérationnel

PLATEFORME D’OPTIMISATION D’ÉQUIPEMENT DE LA CHAÎNE DU FROID (ECF)

Plantilla de plan de despliegue operativo

PLATAFORMA DE OPTIMIZACIÓNDEL EQUIPO DE LA CADENA DE FRÍO

Accelerating typhoid conjugate vaccine introduction

Auteur: PATH

Putting an end to epidemic meningitis in Africa

Auteur: PATH

World Health Statistics 2017: Monitoring health for the SDGs

Auteur: World Health Organization (WHO)

Increasing routine immunization coverage by reducing missed opportunities for vaccination

Auteur: World Health Organization (WHO)

Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017–2026

Auteur: Justus Benzler et al.

Integrating neglected tropical diseases in global health and development

Auteur: World Health Organization (WHO)

Making the leap into the next generation: A commentary on how Gavi, the Vaccine Alliance is supporting countries’ supply chain transformations in 2016–2020

Auteur: Gemma Huckerby, Denise Habimana, Alan Brooks

Access to Vaccines Index 2017

Auteur: Jayasree K. Iyer et al.

Interagency supply chain group Strengthening interagency collaboration: Lessons learned from six countries

Auteur: Hitesh Hurkchand

Global Vaccine Action Plan Secretariat Annual Report 2016

Auteur: World Health Organization (WHO)

When free is not fair: the case of vaccine donations

Auteur: James Smith

Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals

Auteur: Li Liu et al.

World Malaria Report 2016

Auteur: World Health Organization (WHO)

Investing in life saving vaccines to guarantee life of future generations in Africa

Auteur: R.M. Mihigo et al.

Requirements for global elimination of hepatitis B: a modelling study

Auteur: Shevanthi Nayagam et al.

Pneumonia & diarrhea progress report: Reaching goals through action and innovation

Auteur: International Vaccine Access Center (IVAC)

September 2016 VIEW-hub Report on Global Introduction and Implementation

Auteur: International Vaccine Access Center (IVAC)

Global Vaccine Action Plan 2011-2020

Auteur: World Health Organization (WHO)

Immunization eLearning Initiative: Quick Access Guide

Auteur: World Health Organization (WHO)

Summary of the October 2016 meeting of the Strategic Advisory Group of Experts on immunization (SAGE)

Auteur: SAGE

Polio Eradication Initiative (PEI) contribution in strengthening public health laboratories systems in the African region

Auteur: Nicksy Gumede et al.

Case Study: Immunization eLearning Motivation

Auteur: World Health Organization (WHO), UNICEF, Bull City Learning

Keeping children healthy: The Vaccine Alliance Progress Report 2015

Auteur: Gavi, the Vaccine Alliance

Technet Conference Report: 2010

Auteur: World Health Organization (WHO)

Technet Conference Report: 2008

Auteur: World Health Organization (WHO)

Technet Conference Report: 2006

Auteur: World Health Organization (WHO)

Technet Conference Report: 2004

Auteur: World Health Organization (WHO)

Technet Conference Report: 2001

Auteur: World Health Organization (WHO)

Technet Conference Report: 1999

Auteur: World Health Organization (WHO)

Technet Conference Report 1998

Auteur: World Health Organization (WHO)

Technet Conference Report: 1996

Auteur: World Health Organization (WHO)

Technet Conference Report: 1994

Auteur: World Health Organization (WHO)

Technet Conference Report: 1993

Auteur: World Health Organization (WHO)

Technet Conference 1991: Report

Auteur: World Health Organization (WHO)

Technet Conference 1990: Report

Auteur: World Health Organization (WHO)

Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination

Auteur: Wesolowski A et al.

Dengue vaccine: WHO position paper – July 2016

Auteur: World Health Organization (WHO)

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

Auteur: Jeffrey D Stanaway et al.

Polio vaccination: preparing for a change of routine

Auteur: Edward P. K. Parker

A guide for introducing and strengthening Hepatitis B birth dose vaccination

Auteur: Morgan et al.

The State of the World’s Children 2016

Auteur: UNICEF

Quality vaccines for all people ☆: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05–07th October 2015, Bangkok, Thailand

Auteur: Sonia Pagliusi et al.

Zika virus: history of a newly emerging arbovirus

Auteur: Nitwara Wikan et al.

Recovery Toolkit Supporting countries to achieve health service resilience

Auteur: World Health Organization (WHO)

The GAVI Alliance and the ‘Gates approach’ to health system strengthening

Auteur: Katerini T. Storeng

Economic considerations for the eradication endgame

Auteur: Scott Barrett

Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study

Auteur: Amabelia Rodrigues, Ibraima Balde, Manuel Fernandes, Christine S. Benn, Ane B. Fisker, Peter Aaby, Linda Hornshøj

Situation report: zika virus microcephaly guillain-barré syndrome

Auteur: World Health Organization (WHO)

Charting the evolution of approaches employed by GAVI to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999–2014)

Auteur: Gian Gandhi

When is a disease eradicable? 100 years of lessons learned

Eliminating malaria

Auteur: World Health Organization (WHO)

Pneumonia’s second wind? A case study of the global health network for childhood pneumonia

Auteur: David Berlan

GAVI study – outsourcing the distribution component of vaccine and medicine supply chains

Auteur: Gavi, the Vaccine Alliance

Vaccination in acute humanitarian emergencies: a framework for decision making

Auteur: World Health Organization (WHO)

Global routine immunization strategies and practices (GRISP)

Auteur: World Health Organization (WHO)

Ethical considerations for vaccination programmes in acute humanitarian emergencies

Auteur: Keymanthri Moodley et al.

The advance market commitment pilot for pneumococcal vaccines: Outcomes and impact evaluation

Auteur: Gavi, the Vaccine Alliance

Global support for new vaccine implementation in middle-income countries

Auteur: Miloud Kaddar et al.

14th TechNet Conference - 2015: Report

Auteur: TechNet-21

Ebola situation report December 2015: WHO

Auteur: World Health Organization (WHO)

The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

Auteur: Michael Osterholm et al.

Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola

Auteur: Suerie Moon et al.

Pneumonia & Diarrhea Progress Report

Auteur: Thuy-Linh Nguyen et al.

Economic analysis of the global polio eradication initiative

Auteur: Radboud J. Duintjer Tebbens et al.

TechNet Conference 2013: Report

Auteur: TechNet-21

Should remaining stockpiles of smallpox virus (variola) be destroyed?

Auteur: Raymond S. Weinstein

WHO and global health monitoring: The way forward

Auteur: J. Ties Boerma et al.

Technology transfer in human vaccinology: A retrospective review on public sector contributions

Auteur: Jan Hendriks

Towards a more robust investment framework for health

Auteur: Helen Clark

Preparedness for emerging infectious diseases: pathways from anticipation to action

Auteur: V. J. Brookes et al.

Ebola: a crisis in global health leadership

Auteur: Lawrence O Gostinemail, Eric A Friedman

The historical epidemiology of global disease challenges

Auteur: James L A Webb Jr

International donations to the Ebola virus outbreak: too little, too late?

Auteur: Karen Grépin

Keeping score: fostering accountability for children's lives

Auteur: Christopher Murray

World Health Organization guidelines for containment of poliovirus following type-specific polio eradication — worldwide, 2015

Auteur: Nicoletta Previsani et al.

Progress for Children Report

Auteur: UNICEF

Case Studies of IPV introduction: Albania, Nigeria, and Tunisia

Auteur: International Vaccine Access Center (IVAC)

Third Copenhagen Consensus: Infectious disease assessment

Auteur: Dean Jamison et al.

Introduction to PQS - Specifying, testing and pre-qualifying products for use in immunization programmes

Auteur: World Health Organization (WHO)

TechNet Conference 2015 - Conference Guide

Auteur: Dan Brigden

The rocky road to zero: Report of GPEI

Auteur: GPEI - Global Polio Eradication Initiative

Plans for containment of poliovirus following type-specific polio eradication worldwide, 2015

Auteur: Nicoletta Previsani et al.

Proceedings from the inaugural conference of the International Association of Immunization Managers (IAIM)

Auteur: IAIM

The World Health Organization and global smallpox eradication

Auteur: S Bhattacharya

The Global Immunization meeting: Protect, innovate, accelerate: Report

Reimagining Global Health

Auteur: PATH

WHO Director-General addresses vaccine and immunization research forum

Auteur: World Health Organization (WHO)

The Decade of Vaccines Collaboration: developing a global roadmap for saving lives.

Auteur: Chris Elias

Plan d'action mondial pour les vaccins

Auteur: Organisation Mondiale de la Santé (OMS)

Plan de Acción Mundial sobre Vacunas

Auteur: Organización Mundial de la Salud (OMS)

News from the Better Immunization Data (BID) Initiative

Auteur: PATH

La vaccination dans le monde: vision et strat'egie 2006-2015

Auteur: World Health Organization (WHO), UNICEF

Global Vaccine Action Plan. Decade of vaccine collaboration.

Auteur: Decade of Vaccine Collaboration

Global Vaccine Action Plan. Strategic Advisory Group of Experts on Immunization. Assessment Report 2013

Auteur: Strategic Advisory Group of Experts on Immunization (SAGE)

Global Immunization Vision and Strategy 2006-2015

Auteur: World Health Organization (WHO), UNICEF

Global Vaccine Action Plan

Auteur: World Health Organization (WHO)

Gates Foundation's decade of vaccines.

Auteur: The Lancet Infectious Diseases

During the decade of vaccines the lives of 6.4 million children valued at $231 billion could be saved.

Auteur: Andrew Mirelman, David M. Bishai, Meghan L. Stack, Damian G. Walker, Sachiko Ozawa, Louis Niessen, Ingrid K. Friberg

Decade of Vaccines. Editorial.

Auteur: Ciro A. de Quadros, Pedro L. Alonso, Altaf A. Lal, Magdalena Robert

Sixty-fifth world health assembly - Agenda item 13.12: Global vaccine action plan

Auteur: World Health Assembly

Initiatives mondiales

Initiatives mondiales

Thèmes

Du Centre de connaissances

Messages de forum récents

Membres de Technet-21

Événements à venir

Offres d'emploi

Du blog

About

Knowledge Hub

Community

More